Polypid Ltd. has entered into a new research and development collaboration with Immunogenesis Inc. for the development of novel formulations utilizing Polypid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology and Immunogenesis’ potent STING agonist drug candidate to potentially enhance treatment for solid tumors.